<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03702959</url>
  </required_header>
  <id_info>
    <org_study_id>0205 - 18 - RMB</org_study_id>
    <nct_id>NCT03702959</nct_id>
  </id_info>
  <brief_title>Antenatal Betamethasone and the Risk of Neonatal Hypoglycemia</brief_title>
  <official_title>Antenatal Betamethasone and the Risk of Neonatal Hypoglycemia: It's All About Timing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single &quot;supraphysiological&quot; course of exogenous corticosteroids is recommended between
      24-34 weeks' gestation to minimize the adverse sequelae associated with prematurity. The
      24-hour profile of endogenous corticosteroids normally follows a diurnal rhythm with the
      highest serum level occurs between 5am-11am and nadir over 12 hours.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A retrospective study from January 2010 to December 2017. Eligible for analysis are:
      singleton pregnancies between 24 - 34 weeks' gestation who were given a single course of
      intramuscular betamethasone. Single course comprised of two separate doses of 12 mg given 24
      hours apart. Each woman was allocated into one of the four pre-defined groups based on the
      time the intramuscular betamethasone was administered; Group 1 (5am-11am), group 2
      (11am-5pm), group 3 (5pm-11pm) and group 4 (11pm-5am). The investigators hypothesized that
      exogenous corticosteroids given during the nadir state of endogenous corticosteroids activity
      could alter maternal and fetal glucose homeostasis.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>7 Years</target_duration>
  <primary_outcome>
    <measure>Incidence of neonatal hypoglycemia</measure>
    <time_frame>7 years</time_frame>
    <description>Incidence of neonatal hypoglycemia, glucose ˂ 40 mg/dL at any time</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>Betamethasone group 1</arm_group_label>
    <description>Betamethasone Group 1 (5am-11am)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Betamethasone Group 2</arm_group_label>
    <description>Betamethasone Group 2 (11am-5pm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Betamethasone Group 3</arm_group_label>
    <description>Betamethasone Group 3 (5pm-11pm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Betamethasone Group 4</arm_group_label>
    <description>Betamethasone Group 4 (11pm-5am).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betamethasone</intervention_name>
    <description>Corticosteroids</description>
    <arm_group_label>Betamethasone Group 2</arm_group_label>
    <arm_group_label>Betamethasone Group 3</arm_group_label>
    <arm_group_label>Betamethasone Group 4</arm_group_label>
    <arm_group_label>Betamethasone group 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This is a retrospective study at Rambam Health Care Campus.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        • women between 24 - 34 weeks' gestation who were admitted and given a single course of
        intramuscular betamethasone for threatened preterm labor in our institution

        Exclusion Criteria:

          -  higher order multiple pregnancies

          -  women who were given more than one course of betamethasone during the course of the
             current pregnancy

          -  known major congenital anomalies.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant women and their newborns</gender_description>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yaniv Zipori, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yaniv Zipori, M.D</last_name>
    <phone>+972 58 7966963</phone>
    <email>y_zipori@rambam.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rambam health care campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 8, 2018</study_first_submitted>
  <study_first_submitted_qc>October 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2018</study_first_posted>
  <last_update_submitted>October 10, 2018</last_update_submitted>
  <last_update_submitted_qc>October 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rambam Health Care Campus</investigator_affiliation>
    <investigator_full_name>Yaniv Zipori MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The study is expected to be published after completion</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

